Primary Adenocarcinoma of the Bulbomembranous Urethra: Cause or Coincidence?

Peralta Joao Pedro*, Mario Reis¹, Rabaca Carlos² and Amilcar Sismeiro¹

¹Department of Urology, Portuguese Institute of Oncology of Coimbra, Portugal
²Department of Urology, Portuguese Institute of Oncology, Faculty of Medicine of the University of Coimbra, Coimbra, Portugal

Abstract

A 73-year-old male patient was followed in our urology department after prostate cancer in 2004 and bladder cancer in 2011. In April 2013, during the last cystoscopy, a bulbomembranous stricture was found and an urethrotomy was easily performed. Shortly after the procedure, the patient starts complaining of urinary dysfunction and presents with a palpable firm mass in the perineum. An urethroscopy was performed, showing no abnormalities. A pelvic CT-scan was then performed, revealing a complicated and large (6x7x4 cm) post-operative hematoma. After a trial of antibiotics, without any symptomatic improvement, a pelvic MRI showed a large heterogeneous mass, extending to the corporeal bodies and multiple enlarged inguinal and pelvic lymph nodes. He was then submitted to surgical exploration and the pathology report was consistent with primary urethral adenocarcinoma in both the perineum and the corporeal bodies. A new CT scan showed massive metastatic spread. He was proposed for chemotherapy but the prognosis is logically poor.

Background

This case represents a rare condition affecting the urogenital tract, with poor survival and little evidence based medicine. Only a few reports are available in the literature, so no guidelines can be established in a linear fashion.

Case Presentation

A 73-year-old male patient was followed in our urology department after radical prostatectomy for prostate cancer since 2004. He was also under cystoscopic control since 2011 due to bladder cancer. During the last cystoscopy, in April 2013, a bulbomembranous stricture was found, so an urethrotomy was easily performed with no immediate complications. However, shortly after the procedure, the patient starts complaining of urinary dysfunction, comprising hesitancy, poor stream, abdominal effort to urinate and pain to the perineum, which presented with a palpable firm mass.

Upon physical examination, a firm, irregular perineal mass was found with extension to the proximal corporeal bodies.

Investigations

An urethroscopy was performed, showing no abnormalities. A pelvic CT-scan (Figure 1) was performed, revealing a complicated and large (6x7x4 cm) post-operative hematoma. The report had no reference on the corporeal bodies. He was then started on antibiotics and anti-inflammatory drugs for a total of 4 weeks. Because there was no improvement after this course of treatment, and the mass grew larger, a pelvic MRI was performed. The MRI (Figures 2 and 3) showed a large heterogeneous mass, extending to the corporeal bodies, with cystic and solid components and multiple enlarged inguinal lymph nodes, including large necrotic pelvic lymph nodes.

A CT-scan to the thorax, abdomen and pelvis, then revealed major systemic spread to the lymph nodes was detected.

Treatment

He was subjected to surgical exploration of the perineum, with partial excision of the previously referred mass. A biopsy of the corporeal bodies was also performed at that time.

Outcome and Follow-up

The pathology report showed a cystic mass positive for CK7; CK20; CDX-2, PAP, Vimentin Racemase, TTF-1, and S-100 protein on immunohistochemical study, which was consistent with a primary urethral mucinous adenocarcinoma, extending to both the perineum and the corporeal bodies.

After this result, and taking into account the generalized metastatic process, he was only proposed for systemic chemotherapy. An indwelling catheter was needed a few days later because of urinary retention. Despite having been started on chemotherapy, his condition is getting worse and prognosis is poor.

Discussion

Primary carcinoma of the male urethra (UC) is rare, accounting for less than 1% of all urologic malignancies. The majority of those
are Transitional Cell (TCC) and Squamous Cell Carcinomas (SCC). Adenocarcinoma (AC) is even rarer, in both male and female, accounting for less than 6% of all urethral cancers [1,2].

In males, primary carcinomas of the urethra most often appear in the bulbovesical trigone (60%), while the ones occurring in the penile and prostatic urethra are less common (30 and 10%, respectively) [3].

In females, different reports on epidemiology suggest a trend to TCC as well. However, other authors refer a shared incidence with SCC [4].

The aetiology and pathogenesis is unknown, but for male primary UC various predisposing factors have been proposed, which include: urethral strictures, chronic urethritis following sexual transmitted diseases (namely HPV-16), radiation therapy and urethroplasty. In females, however, urethral diverticula and recurrent urinary infections are thought to be associated with tumour’s emergence. Congenital origin may also explain primary AC appearing in younger ages [5,6].

Some prognostic factors have been identified: tumour extension, location at diagnosis and nodal involvement seem to be the most important, as they might predict the amenability to surgical control and complete excision.

Other factors like tumour size, histology, advanced age and race could also have impact on prognosis [7-9]. When they become symptomatic, advanced disease is usually present. The diagnosis is often very difficult, if typical signs and symptoms are not present. Initial hematuria or bloody discharge is usually the signs in about two thirds of the cases. Other symptoms, including extra urethral mass (52%), bladder outlet obstruction (48%), pelvic pain (33%), urethrocystogenous fistula (10%) and low-flow priapism by tumour infiltration to the corporeal bodies have also been reported [10].

Physical examination of the external genitalia with digital rectal exam, bi-manual palpation and inguinal inspection for lymph nodes should be done. Urethrocytoscopyscopy with biopsy or even transurethral resection of visible lesions in the urethra or bladder enables histological assessment. MRI is best suited to define local extent and CT-scan is more accurate in defining metastatic disease to the abdomen and thorax. In contrast with penile cancer, all enlarged lymph nodes should be regarded as metastatic until proved otherwise (30% of the patients are metastatic at presentation) [11-14].

Treatment strategies depend on tumour extent and location, with surgery being the most accepted option when feasible. Prognosis is better for distal tumours, as it allows organ sparing surgery, often with transurethral resection, partial amputation or even distal urethrectomy. When proximal tumours are present and advanced disease is suspected, radical surgery with emasculation is usually performed, with an en bloc resection of the bladder, prostate, urethra along with the penis, scrotum, with or without inferior pubectomy when necessary [15].

Prophylactic bilateral inguinal or pelvic node lymphadenectomy is not advisable. However, it is standard when metastatic lymph nodes are suspected, and is complemented with chemotherapy when distal lymph node disease is present. Retrospective studies in advanced disease with preoperative chemotherapy, with or without radiotherapy before surgery, even with positive lymph nodes, reported good long-term survival, emphasising the need to complete the surgery after chemotherapy.

As only a few cases are described, and because of the lack of randomized trials, chemotherapy regimens are based on similar histological entities in other locations.

As a result, for TCC, MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) and platinum based regimens are often used; although for SCC, similar regimens to penile cancer are the most common option. Because of its even lower incidence, chemotherapy regimens for AC, are sparse, but are usually cisplatin-based [16,17].

Given the low incidence of UC, no proven follow-up regimen has been established. Therefore an individual based-approach should be followed, with a more regular regimen accordingly to organ-sparing strategies [18,19].

Learning Points/Take Home Messages
- Primary urethral cancer is a rare disease with poor prognosis.
- A high degree of suspicion is necessary.
- The lack of randomized trials and valid guidelines makes its treatment an individual challenge.
- An effort should be made to disclose this topic in the urological community, especially by publishing any new data on this matter.

Copyright Statement
I, Joao Pedro Amaral Peralta Lopes , The Corresponding author, has the right to assign on behalf of all authors and does assign on behalf of all authors, a full assignment of all intellectual property rights for all content within the submitted case report and permits this case report (if accepted) to be published.
References


